Amorfix, QPS partner on Alzheimer’s disease diagnostic EP-AD assay project

The partnership will focus on developing and validating the diagnostic EP-AD assay for use as both a biomarker, useful in AD related clinical studies, and an FDA-approved AD early-stage diagnostic.

Amorfix president and CEO Dr. Robert Gundel said, "Our studies using the EP-AD assay demonstrate that the EP-AD assay is able to identify early-stage patients with mild cognitive impairment (MCI) with a sensitivity of 94%, higher than the sensitivity achieved with other biomarkers used as comparators in the same study."

As a part of the project, cerebral spinal fluid will be obtained from Alzheimer’s disease patients present at different stages of disease and will then be analyzed.

QPS CEO Ben Chien said, "To promote successful drug development within this challenging indication, QPS aims to explore new biomarkers that will facilitate early diagnosis and enable meaningful evaluation of drug efficacy for neurodegenerative disorders."